A married father in Sheffield, UK is injecting himself with an unapproved weight-loss drug shipped in unmarked vials from China. Gary Anderton, 45, told reporters he turned to the experimental compound after a mainstream medication did nothing for him.
His story, reported by Bored Panda, has reopened a familiar debate over how far people will go when approved options fail, and what risks they quietly accept to slim down.
What happened
- Gary Anderton, 45, a father of two from Sheffield, injects himself with retatrutide every Monday and Thursday.
- He sources the drug in unmarked vials from a supplier in China, mixes it with sterile water, and stores doses in his fridge for up to a month.
- He previously used semaglutide, which he said produced zero effect even at the highest recommended dose.
- The drug is made by Eli Lilly and is still in late-stage clinical trials; it is not approved for sale in the UK or US.
- Trial data reported by the company in December 2025 showed around 21% of patients on the highest dose experienced skin tingling, and discontinuation rates climbed well above placebo.
What is "reta," and how is it different?
Retatrutide is a triple-agonist injection. Standard GLP-1 drugs like semaglutide (sold as Wegovy and Ozempic) copy one hunger-suppressing hormone. Tirzepatide (Mounjaro, Zepbound) copies two. Retatrutide copies three, adding glucagon, which boosts how many calories the body burns at rest.
In a 2023 Phase 2 trial, patients lost roughly a quarter of their body weight over 48 weeks, and the top-dose groups were still losing weight when the trial ended. In a separate 2025 head-to-head study, tirzepatide users lost around 20% over 72 weeks, versus about 14% for semaglutide.
So the upside is bigger. So is the side-effect list. Patients in trials on the highest doses reported heart-rate jumps of 7 to 10 beats per minute, more than double the bump seen with the older drugs. A December 2025 company release reported dysesthesia, a skin-tingling sensation, in nearly 21% of patients on 12mg. Treatment discontinuation rates reached 18.2% at 12mg against 4% for placebo.
Our analysis
The numbers tell a simple story. More hormonal levers means more weight loss, and more ways for the body to object.
Anderton's case is a window into a fast-growing grey market. Approved drugs are rationed, expensive, or simply don't work for some users. So people start shopping for the next thing before regulators sign off. In online circles the compound is already a meme, swapped between users as casually as a multivitamin code.
Who gains: the patient, if the drug works and they tolerate it. Also peptide sellers and telehealth clinics operating in the gaps between national regulators. Who loses: the official system, which has no visibility into dosing, contamination, or counterfeit supply. And the patient, if the heart-rate bump translates into real cardiac risk years down the line. A 2016 meta-analysis in the Canadian Medical Association Journal linked a sustained 10-beat-per-minute rise to an estimated 8% increase in cardiovascular mortality.
The deeper issue: trials run for months, not years. The muscle, bone, and heart effects of cranking glucagon for a decade are still unknown.
Worked example: what this looks like up close
Say you are someone who has tried semaglutide through a GP and felt nothing. A friend DMs you a Telegram link to a peptide supplier. You wire money to a Chinese vendor, reconstitute the powder with sterile water, and pin a small dose into your stomach twice a week. A few weeks later you are down roughly 15lb and craving nothing. Your resting heart rate has crept upward. Your GP has no idea what you are taking. There is no hotline to ring if something goes wrong.
That gap between "I feel great" and "I am being monitored" is exactly where the risk lives.
What to watch next
Regulators will eventually approve retatrutide or a rival triple agonist. Until then, the underground market will keep filling the queue. Watch three things: whether the UK or US tightens import rules on research peptides, whether telehealth clinics start prescribing "reta" off-label, and whether long-term cardiac data forces an early label change once the drug is real. For now, the only verified patient outcomes are the ones in the trial spreadsheet.
Bottom line: Anderton is happy, the science is undecided. That gap is the whole story.
Key takeaways
- Retatrutide is experimental, not approved, and not monitored once it leaves a clinical trial.
- Higher reported weight-loss numbers come with higher heart-rate jumps and higher dropout rates in trials.
- Buying injectables from overseas suppliers means no quality control, no dose verification, and no doctor in the room if things go wrong.
Frequently asked questions
Is retatrutide legal in the UK or US?
No. According to the report, retatrutide is still in late-stage clinical trials and has not been approved for sale. Anderton obtained it through an overseas supplier.
Why did Anderton skip tirzepatide if his sister had success with it?
According to the report, he chose to go straight to the experimental triple-agonist after reading about it online, even though his sister saw good results from Mounjaro through her doctor.
What side effects did he report?
He said he experienced skin tingling, which he first discovered was a potential side effect after investigating it himself, along with a sharp drop in appetite.
How much weight did he lose?
According to Anderton, he lost 15lb (about 6.8kg) in the first three weeks of using the drug.
What is the biggest known risk?
Trial data cited in the report shows resting heart rate increases of 7 to 10 beats per minute on higher doses, which prior research has linked to an increased risk of cardiovascular mortality.
Inspired by reporting from: boredpanda.com